Pharmaceutical Co., Ltd. MEDICINE CNS/ENDOCRINOLOGY DEVELOPMENT LICENSING COMPANY PROFILE

Transcription

1 WHANIN Pharmaceutical Co., Ltd. MEDICINE CNS/ENDOCRINOLOGY DEVELOPMENT LICENSING COMPANY PROFILE

2 Board of Directors Chairman Vice Chairman President & CEO Vice President, Marketing Director (non-standing) Auditor Mr. Kwang Sik Lee Mr. Keung Lim Kim Mr. Kye Kwan Lee Mr. Kye Ihl Whang Mr. Chong Seok Lee Mr. Hyae Moon Bae Mr. Ki Ock Chang Mr. Chong Dae Kim

3 Management Team Chairman Vice Chairman President & CEO Vice President Sr. Executive Director Executive Director Executive Director Director Director Director Director Director Director KS Lee KL Kim KK Lee KI Hwang SJ Choi BR Park DW Kim KS Hah MS Lee JS Kim SK Park SI Chang SW Lee Founder Sales & Marketing Corporate Sales Marketing Manufacturing Strategy Planning & Adm. BD & Licensing New Product Plan & Regulatory Quality Control Sales Finance

4 Distribution of Shares Name Relation with company Number of Shares % As of Jan. 31, 2003 Kwang Sik Lee Chairman/ Founder 422, Ho Il Park Corp. Consultant 102, Keung Lim Kim Vice President 42, SSB-BAUPOST GL 100, JPMCB-L-R GLB PTNRSLP - 95, ATLANTIS KOREAN SMALLER Other Foreign Investor Shinhan Bank WhanIn Pharm Others Treasury Stock Own Stock Fund 65,880 19, , , ,

5 History Summary Jun, 1978 Dec.1982 Oct Oct Jul Aug.1998 Mar Feb Jan Established as a private owned company Transformed into a limited company Completed KGMP factory at Ansung-city Established Central Research Laboratory Enlisted Korean Stock Exchange Market (Public Company) Korean Good Supply Practice approved Increased the Capital to 9,700 million Won, equivalent USD Million 8.1 Strategic Alliance Signing with Scigenic Corp. for New Drug Development: Alzheimer Drug and 4 New pipelines Mr. Kye-Kwan Lee become new CEO & President

6 Employees Administration 39 (12.4%) R&D 18 (5.7%) Sales & Marketing 172 (54.6%) Production 86 (27.3%) Sales & Marketing 172 ( 54.6%) Administration 39 ( 12.4%) Plant 86 ( 27.3%) R&D 18 ( 5.7%) Total 315(100.0%) As of Jan. 1, 2004

7 Sales/Profit Status: Sales Net Profit Unit : Million Won( ) 55,000 50,000 45,000 40,000 38,680 44,793 48,731 54,000 35,000 31,807 30,000 25,000 23,852 24,436 27,038 20,000 15,000 10,000 5, ,949 9,461 7,095 4,615 9,500 1,994 1,561 2, Year Ended December 31 Ref. Exchange rate : 1,200/USD

8 Operation Status million Won Net income Operating income Ordinary income Estimate Sales 38,679 44,793 48,731 54,000 Operating Income 9,216 11,543 12,558 13,000 Ordinary Income 9,473 13,801 13,665 13,500 Net Income 7,094 8,948 9,461 8,500 Year Ended December 31 Unit: Million Won, Foreign. Exchange rate : W1,200/USD

9 Leading Products Value million Won 8,000 7,000 6,000 5,000 4,000 3,000 2,000 1, Alend Tab. Grandaxin Tab. Ubacillin inj. Alpram Tab. Acamprol Tab Alend Tab Osteoporosis treatment 4,317 6,890 7,130 Grandaxin Tab Tranquilizer 3,130 4,318 4,318 Ubacillin Inj Antibiotic 3,508 2,046 1,496 Alpram Tab Tranquilizer 2,299 2,333 2,410 Acamprol Tab Antialcoholism 925 1,857 2,120

10 Revenue 2002 by Therapeutic class 16% 5% 7% 6% Cardiovascular drugs Others Psychotherapeutics 11% Antimicrobials GI tract drugs 9% 9% 40% NSAIDs Osteoporosis agents Topical As of Dec. 31, 2002

11 Foreign Tie-ups License Agreement Suntory (Japan) Yamanouchi Pharm. (Japan) Lundbeck A/S (Denmark) RPR (Pharmuka S.F. : France) Lisapharma (Italy) Hovion (Portugal) Egis (Hungary) Gador (Argentina) Distribution Agreement Doetsch Grether AG (Swiss) Celltech (USA) HANP Inj. (Carperitide ) Neponid Tab. (Nemonapride ) Clopixol Tab. (Zuclopenthixol ) Cipram Tab. (Citalopram ) Kinupril Tab. (Quinupramine ) Pirxane Cap. (Buflomedil pyridoxal Phosphate ) Dexaderm Cream (Dexamethasone propionate ) Grandaxin Tab. (Tofisopam ) Alend (Alendronate ) Sulgan99 Oint./Supp. Zaroxolyn (Metolazone ) Acute Heart Failure Antipsychotic Antipsychotic Antidepressant Antidepressant Cerebral & Peripheral Vasodilator Non habit Forming Tranquilizer Osteoporosis Treatment Antihemorrhoid Diuretic

12 Branch Regional Offices: Total 16

13 Factory Dosage Forms : Tablets Capsules Injections (Ampoule, Vial, Penicillin) Topicals (Cream, Ointment, Solution) Oral Liquids Land Space : 10,000 m 2 Building Space : 9,000 m 2 Location : Ansung city, Kyungki-do

14 Balance Sheet (Unit : Million Won) Ref. Exchange rate : 1,200/US$ Dec. 31,2002 Dec.31,2001 Dec. 31,2000 Assets 64,701 58,453 59,030 Current Assets 48,742 41,634 41,343 Non-Current Assets 15,960 16,819 17,687 Liabilities 7,985 10,462 12,228 Current Liabilities 6,180 8,894 8,819 Fixed Liabilities 1,836 1,568 3,409 Shareholders equity 56,685 47,991 46,802 Debt ratio(%)

15 Income Statement (Unit : Million Won) Ref. Exchange rate : 1,200/USD Year Ended December Sales 48,731 44,792 38,680 Cost of Sales 17,748 16,314 14,817 Gross Profit 30,983 28,478 23,863 Operating Income 12,558 11,542 9,217 Ordinary Income 13,665 13,080 9,474 Income Taxes 4,205 4,132 2,379 Net Income 9,461 8,948 7,095